As of the beginning of 2017, the Finnish Pharmaceuticals Pricing Board (Hila) has had the authority to decide on the conditional reimbursement and the wholesale price for medicinal products. The risk-sharing model of conditional reimbursement enables a more rapid and frequent introduction of medicinal products containing either new active substances or new indications for medicinal […]